Planned enrollment decreased by 51 participants
Before: 401 participants (planned). After: 350 participants (planned).
Study sponsor: Acrivon Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: 401 participants (planned). After: 350 participants (planned).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).. After: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers). Measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers)..
Before: 353 participants (planned). After: 401 participants (planned).
Before: 31 Oct 2026. After: 30 May 2027.